Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

StatusRecruiting
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 107 → 127 locations
    • Eligibility criteria expanded, about 34 words
    • Secondary endpoints: details revised at 1 of 9 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Study sites: 77 to 107v9
  3. Study sites: 57 to 77v8
  4. Study sites: 46 to 57
    • Study title revised
    v7
  5. Study sites: 12 to 46v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date changed from estimate of Apr 2025 to May 22, 2025v5
  2. Study sites: 3 to 12v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 2024 to Apr 2025
    • Study sites: 0 to 3
    v3
  4. Study title shortened, about 7 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Trial Details
NCT Number NCT06697301
Lead Sponsor Eikon Therapeutics
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Advanced Melanoma
Related terms Neoplasm Metastasis
Enrollment 740 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov